Biogen to pay $22M to settle ‘kickback’ allegations

Biogen Inc. has agreed to a $22 million settlement after federal prosecutors accused the Cambridge-based biotech of using two foundations to pay Medicare co-pays for patients taking its multiple sclerosis drugs.